Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9701735-B2
Publication Date
2017-07-11
Expiration Date
Abstract
The disclosure provides improved compositions and methods for passive immunization. In embodiments, a composition comprising a synergistic combination of specific polyclonal antibodies in a carrier matrix is provided. The disclosure provides effective, economical compositions and methods for the treatment of diarrhea and enteric infections in broad-spectrum, undifferentiated, or mixed clinical applications.
Core Innovation
The invention relates to passive immunization compositions for treatment of diarrhea or enteric infection in a non-neonate human in need thereof. The compositions include a non-neonate human effective amount of at least one specific binding molecule comprising a mixture of IgY antibodies specific for antigens derived from Escherichia coli, rotavirus, and coronavirus pathogens, and pathogen related toxins and/or pathogen related adhesion elements.
The compositions additionally include a carrier matrix comprising a matrix obtained from, isolated from, or derived from non-hyperimmune bovine colostrum. The disclosed composition scope supports use in a non-neonate human effective amount for undifferentiated diarrhea, undifferentiated pediatric diarrhea, traveler's diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, and gastrointestinal flora management.
In the disclosed composition scope, the specific binding molecules are configured as a mixture of IgY antibodies that target the listed antigen sources, together with pathogen related toxins and/or pathogen related adhesion elements. The carrier matrix is derived from non-hyperimmune bovine colostrum, and the overall concept supports use in a non-neonate human effective amount for the enumerated diarrhea and enteric infection indications.
Claims Coverage
The document includes two independent claims, directed to a composition for treating diarrhea or enteric infection in a non-neonate human and a method of treating diarrhea or enteric infection in a non-neonate human by administering the composition. The inventive features across the independent claims emphasize a mixture of IgY antibodies with specified antigen targets combined with a non-hyperimmune bovine colostrum carrier matrix for defined diarrhea and enteric infection indications.
Non-neonate effective IgY mixture with pathogen toxin/adhesion targeting
A non-neonate human effective amount of at least one specific binding molecule, wherein the at least one specific binding molecules comprise a mixture of IgY antibodies specific for antigens derived from Escherichia coli, rotavirus, and coronavirus pathogens, pathogen related toxins, and/or pathogen related adhesion elements.
Non-hyperimmune bovine colostrum carrier matrix
A carrier matrix comprising a matrix obtained from, isolated from, or derived from non-hyperimmune bovine colostrum.
Treatment of enumerated diarrhea and enteric infection indications in non-neonate humans
Wherein the human non-neonate effective amount is for the treatment of undifferentiated diarrhea, undifferentiated pediatric diarrhea, traveler's diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, or for gastrointestinal flora management.
Administration method for non-neonate diarrhea and enteric infection treatment
The method comprising administration of a composition comprising a non-neonate human effective amount of at least one specific binding molecule comprising a mixture of IgY antibodies specific for antigens derived from Escherichia coli, rotavirus, and coronavirus pathogens, pathogen related toxins, and/or pathogen related adhesion elements; and a carrier matrix comprising a matrix obtained from, isolated from, or derived from non-hyperimmune bovine colostrum, wherein the non-neonate human effective amount is for the treatment of undifferentiated diarrhea, undifferentiated pediatric diarrhea, traveler's diarrhea, rotavirus diarrhea, toxin-mediated diarrhea, cholera, C. difficile infection, dysentery, typhoid fever, peptic ulcers, or for gastrointestinal flora management.
Across the independent claims, coverage centers on administering or providing a composition that combines a non-neonate human effective amount of IgY antibody mixtures, including specificity for Escherichia coli, rotavirus, and coronavirus antigens plus pathogen related toxins and/or adhesion elements, with a carrier matrix derived from non-hyperimmune bovine colostrum, for the explicitly listed diarrhea and enteric infection indications and gastrointestinal flora management.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?